Bullish option flow detected in Crispr Therapeutics with 3,269 calls trading, 2x expected, and implied vol increasing over 2 points to 67.35%. Jan-23 60 calls and Jan-25 50 puts are the most active options, with total volume in those strikes near 1,500 contracts. The Put/Call Ratio is 0.30. Earnings are expected on February 14th.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CRSP:
- Crispr Therapeutics initiated with a Buy at EF Hutton
- Crispr Therapeutics appoints Harding as SVP, Head of Business Development
- CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business Development
- Crispr Therapeutics provides update on ongoing Phase 1 CARBON trial
- CRISPR Therapeutics Provides Update on Its Ongoing Phase 1 CARBON™ Trial of CTX110®
